James M. McGill

James M. McGill

Auto-generated profile, based on publicly available information

James M. McGill

Indiana University Health, Indianapolis, IN

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1995 in Gastroenterology
Verified
Journal Article
Open access
AKAnn P. Kwiatkowski
Ann P. Kwiatkowski
JMJames M. McGill
James M. McGill
Calmodulin-dependent protein kinase II is a family of closely related multimeric enzymes that regulate a wide variety of cellular processes. In biliary epithelial cells, this kinase seems to regulate Ca(2+)-dependent CI- currents. The aim of this study was to identify isoforms of this kinase expressed in biliary cells. Sequencing of reverse-transcription polymerase chain reaction products identified multiple isoforms in Mz-ChA-1 cells. Two previously identified isoforms (gamma B and gamma C) and three new isoforms (gamma D, gamma E, and gamma F) of calmodulin-dependent protein kinase II were identified. Each of the novel isoforms contains a unique insert of 114 base pairs in the association region. This insert lies outside the previously identified variable region. In addition, gamma D and gamma F contained other deletions (42 and 69 base pairs, respectively) in the variable region. These isoforms are expressed in a variety of tissues, including biliary epithelial and gallbladder cells, but only gamma C is expressed in rat hepatocytes. Identification of these biliary kinase isoforms paves the way for future studies that will elucidate the role of individual isozymes in agonist-stimulated biliary Cl- and fluid secretion.

1 March 1996 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JMJames M. McGill
James M. McGill
DWDiane M. Williams
Diane M. Williams
CHChristine M. Hunt
Christine M. Hunt

1 June 2025 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
HCHongyu Chen
Hongyu Chen
XLXiaohan Li
Xiaohan Li
XHXing He
Xing He
ACAokun Chen
Aokun Chen
JMJames McGill
James McGill
Jiang BianJiang Bian
Jiang Bian
PURPOSE: Patient recruitment remains a major bottleneck in clinical trial execution, with inefficient patient-trial matching often causing delays and failures. Recent advancements in large language models (LLMs) offer a promising avenue for automating and improving this process. This scoping review aims to provide a comprehensive synthesis of the emerging applications of LLMs in patient-trial matching. METHODS: A comprehensive search was conducted in PubMed, Web of Science, and OpenAlex for literature published between December 1, 2022, and December 31, 2024. Studies were included if they explicitly integrated LLMs into patient-trial matching systems. Data extraction focused on system architectures, patient data processing, eligibility criteria processing, matching techniques, evaluation metrics, and performance. RESULTS: Of the 2,357 studies initially identified, 24 met the inclusion criteria. The majority (21/24) were published in 2024, highlighting the rapid adoption of LLMs in this domain. Most systems used patient-centric matching (17/24), with OpenAI's generative pretrained transformer models being the most commonly used LLM. Core components of these systems included eligibility criteria processing, patient data processing, and matching, with some incorporating retrieval algorithms to enhance computational efficiency. LLM-integrated approaches demonstrated improved accuracy and scalability in patient-trial matching, although challenges such as performance variability, interpretability, and reliance on synthetic data sets remain significant. CONCLUSION: LLM-based patient-trial matching systems present a transformative opportunity to enhance the efficiency and accuracy of clinical trial recruitment. Despite current limitations related to model generalizability, explainability, and data constraints, future advancements in hybrid modeling strategies, domain-specific fine-tuning, and real-world data set integration could further optimize LLM-based trial matching. Addressing these challenges will be crucial to realizing the full potential of LLMs in streamlining patient recruitment and accelerating clinical trial execution.